BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln

Reuters01-13

Jan 12 (Reuters) - Sarepta Therapeutics Inc SRPT.O:

SAREPTA REPORTS PRELIMINARY* FOURTH QUARTER AND FULL-YEAR 2025 NET PRODUCT REVENUES
SAREPTA THERAPEUTICS Q4 REVENUE USD 369.6 MILLION VS. IBES ESTIMATE USD 351.7 MILLION
SAREPTA THERAPEUTICS INC - Q4 NET PRODUCT REVENUE FOR ELEVIDYS TOTALED $110.4 MLN
SAREPTA THERAPEUTICS INC: RECONFIRM YEARLY SALES FLOOR FOR ELEVIDYS OF $500.0 MLN

Source text: ID:nBw3ZlYCqa

Further company coverage: SRPT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603452330?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 03:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603452330","market":"us","top_or_hot":-1,"title":"BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> Inc <span>SRPT.O</span>:</p><ul><li><p>SAREPTA REPORTS PRELIMINARY* FOURTH QUARTER AND FULL-YEAR 2025 NET PRODUCT REVENUES</p></li><li><p>SAREPTA THERAPEUTICS Q4 REVENUE USD 369.6 MILLION VS. IBES ESTIMATE USD 351.7 MILLION</p></li><li><p>SAREPTA THERAPEUTICS INC -  Q4 NET PRODUCT REVENUE FOR ELEVIDYS TOTALED $110.4 MLN</p></li><li><p>SAREPTA THERAPEUTICS INC: RECONFIRM YEARLY SALES FLOOR FOR ELEVIDYS OF $500.0 MLN</p></li></ul><p>Source text: <span>ID:nBw3ZlYCqa</span></p><p>Further company coverage: <span>SRPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-13 03:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 Mln</title></head><body><p><span>Jan 12 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRPT\">Sarepta Therapeutics</a> Inc <span>SRPT.O</span>:</p><ul><li><p>SAREPTA REPORTS PRELIMINARY* FOURTH QUARTER AND FULL-YEAR 2025 NET PRODUCT REVENUES</p></li><li><p>SAREPTA THERAPEUTICS Q4 REVENUE USD 369.6 MILLION VS. IBES ESTIMATE USD 351.7 MILLION</p></li><li><p>SAREPTA THERAPEUTICS INC -  Q4 NET PRODUCT REVENUE FOR ELEVIDYS TOTALED $110.4 MLN</p></li><li><p>SAREPTA THERAPEUTICS INC: RECONFIRM YEARLY SALES FLOOR FOR ELEVIDYS OF $500.0 MLN</p></li></ul><p>Source text: <span>ID:nBw3ZlYCqa</span></p><p>Further company coverage: <span>SRPT.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA1BYP1K:1","article_id":"2603452330","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603452330","pubTimestamp":1768245569,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 MlnJan 12 (Reuters) - Sarepta Therapeutics Inc SRPT.O:SAREPTA REPORTS PRELIMINARY* FOURTH QUARTER AND FULL-YEAR 2025 NET PRODUCT REVE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4139":"生物科技","SRPT":"Sarepta Therapeutics","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD"},"translate_title":"简介-Sarepta再次确认ELEVIDYS的年销售额为5亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":0.9},"content_text":"BRIEF-Sarepta Reconfirms Yearly Sales Floor For ELEVIDYS Of $500.0 MlnJan 12 (Reuters) - Sarepta Therapeutics Inc SRPT.O:SAREPTA REPORTS PRELIMINARY* FOURTH QUARTER AND FULL-YEAR 2025 NET PRODUCT REVENUESSAREPTA THERAPEUTICS Q4 REVENUE USD 369.6 MILLION VS. IBES ESTIMATE USD 351.7 MILLIONSAREPTA THERAPEUTICS INC -  Q4 NET PRODUCT REVENUE FOR ELEVIDYS TOTALED $110.4 MLNSAREPTA THERAPEUTICS INC: RECONFIRM YEARLY SALES FLOOR FOR ELEVIDYS OF $500.0 MLNSource text: ID:nBw3ZlYCqaFurther company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603452330","isCrawlerRequest":true}